Log in to search using one of your social media accounts:

 

EU Approves Trelegy Ellipta for COPD EU Approves Trelegy Ellipta for COPD
The European Commission has granted marketing authorization for fluticasone furoate/umeclidinium/vilanterol (Trelegy Ellipta, GlaxoSmithKline PLC and Innoviva, Inc) for the treatment of COPD.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 16, 2017 Category: Consumer Health News Tags: Pulmonary Medicine News Alert Source Type: news

fluticasone (Flonase, Flonase Allergy Relief)
Title: fluticasone (Flonase, Flonase Allergy Relief)Category: MedicationsCreated: 3/26/1998 12:00:00 AMLast Editorial Review: 11/10/2017 12:00:00 AM (Source: MedicineNet Allergies General)
Source: MedicineNet Allergies General - November 10, 2017 Category: Allergy & Immunology Source Type: news

Flonase vs. Nasacort
Title: Flonase vs. NasacortCategory: MedicationsCreated: 10/30/2017 12:00:00 AMLast Editorial Review: 10/30/2017 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - October 30, 2017 Category: Drugs & Pharmacology Source Type: news

Trelegy Ellipta (Fluticasone Furoate Inhalation Powder) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 28, 2017 Category: Drugs & Pharmacology Source Type: news

Xhance (Fluticasone Propionate Nasal Spray, for Intranasal Use) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 28, 2017 Category: Drugs & Pharmacology Source Type: news

Xhance ™ (fluticasone propionate) for the Treatment of Nasal Polyps
Xhance ™ (fluticasone propionate / previously known as OPN-375), a synthetic trifluorinated corticosteroid, is indicated for the treatment of nasal polyps in patients aged 18 years or older. (Source: Drug Development Technology)
Source: Drug Development Technology - September 26, 2017 Category: Pharmaceuticals Source Type: news

FDA Approves Trelegy Ellipta for COPD FDA Approves Trelegy Ellipta for COPD
The FDA has approved once-daily, single inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol (Trelegy Ellipta, GlaxoSmithKline) for patients with COPD.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 19, 2017 Category: Consumer Health News Tags: Pulmonary Medicine News Alert Source Type: news

FDA approves GSK ’ s 3-in-1 Trelega Ellipta inhaler
The FDA has approved the triple inhaler developed by GlaxoSmithKline (NYSE:GSK) and Innoviva (NSDQ:INVA) to treat chronic obstructive pulmonary disease, the companies reported today. The Trelega Ellipta dry powder inhaler uses fluticasone furoate, umeclidinium and vilanterol to help adults with COPD manage the condition. It is the first once-daily product approved in the U.S. that combines three active molecules in a single inhaler for COPD patients. Get the full story at our sister site, Drug Delivery Business News. The post FDA approves GSK’s 3-in-1 Trelega Ellipta inhaler appeared first on Mass...
Source: Mass Device - September 19, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Respiratory Wall Street Beat GlaxoSmithKline plc Innoviva Source Type: news

Optinose Announces FDA Approval of Xhance (fluticasone propionate) Nasal Spray for the Treatment of Nasal Polyps
YARDLEY, Pa.--(BUSINESS WIRE)-- September 18, 2017 -- Optinose, an ENT / Allergy specialty pharmaceutical company, announced today that the U.S. Food& Drug Administration (FDA) approved the Company ’s New Drug Application (NDA) for Xhance... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 19, 2017 Category: Drugs & Pharmacology Source Type: news

FDA Approves Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) for the Treatment of COPD
London UK – 18 September 2017 -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the US Food and Drug Administration (FDA) has approved once-daily, single inhaler triple therapy fluticasone... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 18, 2017 Category: Drugs & Pharmacology Source Type: news

CHMP Backs Two New Inhalers Inhalers for COPD CHMP Backs Two New Inhalers Inhalers for COPD
Elebrato Ellipta and Trelegy Ellipta contain the triple combination of fluticasone furoate, umeclidinium, and vilanterol and are for inadequately controlled moderate to severe COPD in adults.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 15, 2017 Category: Consumer Health News Tags: Pulmonary Medicine News Alert Source Type: news

EMA Panel Backs Two New Inhalers for COPD EMA Panel Backs Two New Inhalers for COPD
Elebrato Ellipta and Trelegy Ellipta contain the triple combination of fluticasone furoate, umeclidinium, and vilanterol and are for inadequately controlled moderate to severe COPD in adults.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 15, 2017 Category: Consumer Health News Tags: Pulmonary Medicine News Alert Source Type: news

GSK ’s triple-med COPD inhaler wins recommendation for approval in EU
GlaxoSmithKline (NYSE:GSK) and Innoviva (NSDQ:INVA) said today that a European Medicines Agency panel recommended marketing authorization for the Trelegy Ellipta triple-combination inhaler for adults with COPD. The device uses fluticasone furoate, umeclidinium and vilanterol to help adults with COPD who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist. It’s also the first once-daily single inhaler triple therapy to win a positive opinion by the Committee for Medicinal Products for Human Use, the companies reported. Get the full story at our sister...
Source: Mass Device - September 15, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Pharmaceuticals Regulatory/Compliance Respiratory Wall Street Beat GlaxoSmithKline plc Innoviva Source Type: news

Fluticasone Furoate Slows Loss of Lung Function in COPD
Alone or in combination, reduces rate of FEV1 decline in those with moderate COPD and high risk of CVD (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - August 4, 2017 Category: Respiratory Medicine Tags: Cardiology, Pharmacy, Pulmonology, Journal, Source Type: news

Dymista (Azelastine Hydrochloride and Fluticasone Propionate) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 1, 2017 Category: Drugs & Pharmacology Source Type: news

GSK files supplementary NDA for asthma treatment arnuity ellipta
GSK has submitted a supplementary new drug application (sNDA) to the US Food and Drug Administration (FDA) for the use of arnuity ellipta (fluticasone furoate) as a maintenance treatment of children with asthma. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - July 25, 2017 Category: Pharmaceuticals Source Type: news

Dymista (Azelastine Hydrochloride and Fluticasone Propionate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 6, 2017 Category: Drugs & Pharmacology Source Type: news

Novartiz unit Sandoz seeks FDA nod for generic Advair Diskus
Novartis (NYSE:NVS) unit Sandoz said today that the FDA has accepted the abbreviated new drug application for its generic version of Advair Diskus. The fluticasone propionate/salmeterol device is designed to treat asthma in patients ages 4 and older, as well as provide maintenance treatment of airflow obstruction and reduce exacerbations in patients with chronic obstructive pulmonary disease. Get the full story at our sister site, Drug Delivery Business News. The post Novartiz unit Sandoz seeks FDA nod for generic Advair Diskus appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - June 16, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Respiratory Wall Street Beat Amgen Novartis sandoz Source Type: news

Veramyst (Fluticasone Furoate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 16, 2017 Category: Drugs & Pharmacology Source Type: news

Breo Ellipta (Fluticasone Furoate and Vilanterol Inhalation Powder) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 26, 2017 Category: Drugs & Pharmacology Source Type: news

US FDA issues CRL to Hikma ’s generic version of GSK’s Advair Diskus
Hikma Pharmaceuticals has received a complete response letter (CRL) from the US Food and Drug Administration (FDA) for the abbreviated new drug application (ANDA) of its generic version of GlaxoSmithKline's Advair Diskus (fluticasone propionate and s … (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - May 11, 2017 Category: Pharmaceuticals Source Type: news

8 Things You Need To Know About Your Body's Energy Levels
By Hallie Levine Your energy makeover starts now It’s no wonder so many of us struggle with energy issues. We go, go, go from morning to night, running on little but grit and caffeine. But it doesn’t have to be that way! “The reality is, you can get a real boost by making a few simple changes,” says Nada Milosavljevic, MD, director of the integrative health program at Massachusetts General Hospital. That’s why we put together this complete guide to all-day energy: It’s packed with proven strategies that will keep you powered up as you plow through your to-do list. You’ll also learn...
Source: Healthy Living - The Huffington Post - May 4, 2017 Category: Consumer Health News Source Type: news

Teva launches AirDuo RespiClick, generic inhaled asthma therapies
Teva Pharmaceutical (NYSE:TEVA) said today that it launched the AirDuo RespiClick inhalation therapy and its authorized generic in the U.S. for asthma patients who are uncontrolled on an inhaled corticosteroid. AirDuo RespiClick and the generic are fixed-dose combination therapies contained fluticasone propionate and salmeterol – the same active ingredients as Advair. The therapies are delivered using Teva’s breath-activated RespiClick inhaler. Get the full story at our sister site, Drug Delivery Business News. The post Teva launches AirDuo RespiClick, generic inhaled asthma therapies appeared first on Mas...
Source: Mass Device - April 20, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Drug-Device Combinations Pharmaceuticals Respiratory Wall Street Beat Teva Pharmaceuticals Source Type: news

GSK Consumer Healthcare Launches FLONASE(R) Sensimist(TM) Allergy Relief Nationwide
WARREN, N.J., Feb. 8, 2017 -- (Healthcare Sales & Marketing Network) -- GSK Consumer Healthcare today announced the nationwide launch of FLONASE® Sensimist™ Allergy Relief (fluticasone furoate, 27.5 mcg spray), a new over-the-counter (OTC) treatment f... Biopharmaceuticals, Product Launch GlaxoSmithKline, GSK Consumer Healthcare, FLONASE, fluticasone, Sensimist (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 8, 2017 Category: Pharmaceuticals Source Type: news

ArmonAir RespiClick (Fluticasone Propionate Multidose Dry Powder Inhaler for Oral Inhalation) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 8, 2017 Category: Drugs & Pharmacology Source Type: news

AirDuo RespiClick Inhalation Powder (Fluticasone Propionate and Salmeterol) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 8, 2017 Category: Drugs & Pharmacology Source Type: news

Teva Announces FDA Approval of ArmonAir RespiClick (fluticasone propionate) for Maintenance Treatment of Asthma
JERUSALEM--(BUSINESS WIRE) January 30, 2017 --Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved ArmonAir RespiClick (fluticasone propionate inhalation powder) for... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 31, 2017 Category: Drugs & Pharmacology Source Type: news

Teva Announces FDA Approval of AirDuo RespiClick (fluticasone propionate and salmeterol) for Maintenance Treatment of Asthma
JERUSALEM--(BUSINESS WIRE) January 30, 2017 --Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved AirDuo RespiClick (fluticasone propionate and salmeterol... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 30, 2017 Category: Drugs & Pharmacology Source Type: news

GSK and Innoviva begin Phase III Captain study of triple combination therapy to treat asthma
GlaxoSmithKline (GSK) and Innoviva have initiated a Phase III Captain study of a triple combination therapy consisting of fluticasone furoate / umeclidinium / vilanterol (FF/UMEC/VI) compared to dual combination therapy of Relvar / Breo (FF/VI) to tr … (Source: Drug Development Technology)
Source: Drug Development Technology - December 20, 2016 Category: Pharmaceuticals Source Type: news

GSK launches phase III trial for inhaled triple combination therapy
GlaxoSmithKline (NYSE:GSK) and Innoviva (NSDQ:INVA) said today that they launched a phase III trial evaluating the triple combination therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) in patients with asthma. The companies’ triple combination therapy is made up of 3 drugs – an inhaled corticosteroid, a long-acting muscarinic antagonist, and a long-acting beta-adrenergic agonist. The treatment is delivered once a day using GSK’s Ellipta dry powder inhaler. Get the full story at our sister site, Drug Delivery Business News. The post GSK launches phase III trial for in...
Source: Mass Device - December 19, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Pharmaceuticals Respiratory GlaxoSmithKline plc Innoviva Source Type: news

GSK, Innoviva seek EU nod for triple combo inhaled therapy
GlaxoSmithKline (NYSE:GSK) and Innoviva (NSDQ:INVA) said last week that they filed a regulatory submission with the European Medicines Agency for the once-daily, triple-combination therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) for patients with chronic obstructive pulmonary disease. Last month, the companies submitted a new drug application for the inhaled therapy to the FDA for approval in the U.S. The triple combination therapy is made up of 3 drugs – an inhaled corticosteroid, a long-acting muscarinic antagonist, and a long-acting beta-adrenergic agonist. The treatm...
Source: Mass Device - December 5, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Drug-Device Combinations Pharmaceuticals Regulatory/Compliance Respiratory AstraZeneca plc GlaxoSmithKline plc Innoviva Source Type: news

Advair HFA (Fluticasone Propionate and Salmeterol) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 22, 2016 Category: Drugs & Pharmacology Source Type: news

Cutivate Lotion (Fluticasone Propionate Lotion) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 22, 2016 Category: Drugs & Pharmacology Source Type: news

Flonase (Fluticasone Propionate Nasal Spray) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 22, 2016 Category: Drugs & Pharmacology Source Type: news

GSK files regulatory submission with US FDA for FF / UMEC / VI therapy
GlaxoSmithKline (GSK) and Innoviva have filed a regulatory submission with the US Food and Drug Administration (FDA) for fluticasone furoate / umeclidinium / vilanterol (FF / UMEC / VI 100mcg / 62.5mcg / 25mcg) therapy for patients with chronic obstr … (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - November 22, 2016 Category: Pharmaceuticals Source Type: news

GSK files for FDA approval of inhaled triple-combo therapy for COPD
GlaxoSmithKline (NYSE:GSK) and Innoviva (NSDQ:INVA) said today that GSK filed a regulatory submission with the FDA for the once-daily, closed triple combination therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) for patients with chronic obstructive pulmonary disease. The triple-combo therapy includes 3 drugs: fluticasone furoate, an inhaled corticosteroid; umeclidinium, a long-acting muscarinic antagonist; vilanterol, a long-acting beta2-adrenergic agonist. The medicines are delivered once-daily using GSK’s Ellipta dry powder inhaler. Get the full story at our sister site, Drug Delivery Busin...
Source: Mass Device - November 21, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Regulatory/Clearance Respiratory AstraZeneca plc GlaxoSmithKline plc Innoviva Source Type: news

Flovent Diskus (Fluticasone Propionate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 10, 2016 Category: Drugs & Pharmacology Source Type: news

Advair Diskus, Advair HFA (fluticasone and salmeterol oral inhaler)
Title: Advair Diskus, Advair HFA (fluticasone and salmeterol oral inhaler)Category: MedicationsCreated: 1/22/2002 12:00:00 AMLast Editorial Review: 11/7/2016 12:00:00 AM (Source: MedicineNet Asthma General)
Source: MedicineNet Asthma General - November 7, 2016 Category: Respiratory Medicine Source Type: news

Cutivate Ointment (Fluticasone Propionate Ointment) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - October 31, 2016 Category: Drugs & Pharmacology Source Type: news

GlaxoSmithKline ’ s triple combo with Innoviva tops Symbicort Turbohaler in COPD
GlaxoSmithKline (NYSE:GSK) and Innoviva (NSDQ:INVA) yesterday touted results from a Phase III study investigating the triple-combination therapy fluticasone furoate/umeclidnium/vilanterol for patients with chronic obstructive pulmonary disease. The 1,810-patient Fulfil study is a randomized, double-blinded trial comparing once-daily FF/UMEC/VI against AstraZeneca‘s (NYSE:AZN) Symbicort Turbohaler dry powder inhaler, a twice-daily combination of budesonide and formoterol. Patients in the FF/UMEC/VI arm showed improved lung function and fewer of the exacerbations normally seen in COPD patients. After 24 weeks...
Source: Mass Device - September 7, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Research & Development AstraZeneca plc GlaxoSmithKline plc Innoviva Source Type: news

Fluticasone-Vilanterol Regimen Tied to Lower Risk for COPD Exacerbations (FREE)
By Kelly Young Edited by David G. Fairchild, MD, MPH Combination fluticasone furoate-vilanterol is associated with reduced risk for chronic obstructive pulmonary disease (COPD) exacerbations. The results of the industry-conducted, open-label study were presented at the European … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - September 5, 2016 Category: Primary Care Source Type: news

FDA Approves FLONASE(R) Sensimist(TM) Allergy Relief
WARREN, N.J., Aug. 3, 2016 -- (Healthcare Sales & Marketing Network) -- GSK Consumer Healthcare announced today that the U.S. Food and Drug Administration (FDA) has approved FLONASE® Sensimist™ Allergy Relief (fluticasone furoate, 27.5 mcg spray) as a... Biopharmaceuticals, FDA GlaxoSmithKline, FLONASE, Sensimist, fluticasone (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 3, 2016 Category: Pharmaceuticals Source Type: news

FDA Approves Flonase Sensimist Allergy Relief
WARREN, N.J. 2 August 2016 -- GSK Consumer Healthcare announced today that the U.S. Food and Drug Administration (FDA) has approved Flonase ® Sensimist™ Allergy Relief (fluticasone furoate, 27.5 mcg spray) as an over-the-counter (OTC) treatment... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 2, 2016 Category: Drugs & Pharmacology Source Type: news

Flovent HFA (Fluticasone Propionate HFA) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 26, 2016 Category: Drugs & Pharmacology Source Type: news

Advair Diskus (Fluticasone Propionate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 23, 2016 Category: Drugs & Pharmacology Source Type: news

fluticasone and salmeterol oral inhaler, Advair Diskus, Advair HFA
Title: fluticasone and salmeterol oral inhaler, Advair Diskus, Advair HFACategory: MedicationsCreated: 1/22/2002 12:00:00 AMLast Editorial Review: 5/18/2016 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - May 18, 2016 Category: Drugs & Pharmacology Source Type: news

What 5 Nurses Keep In Their Medicine Cabinets
Snooping inside a medicine cabinet while using the bathroom during a party is a particular guilty pleasure.  What eye cream does your host use? What kinds of medications are they on? It’s natural to be curious and often, you’re comparing the regimens of acquaintances to your own. For example, do you have the same emergency first aid stash?   If you’re snooping inside the medicine cabinet of a nurse, you might feel the strong urge to copy what you see. In this case, HuffPost has done the peeking for you: Among the nurses contacted for this story, over-the-counter painkillers, bandages and to...
Source: Science - The Huffington Post - May 12, 2016 Category: Science Source Type: news

Asthma Patients Treated Safely with Salmeterol-Fluticasone Combo
An FDA-mandated study finds use of LABA plus ICS in a single inhaler noninferior to ICS alone with regard to serious asthma outcomes. (Source: ConsultantLive)
Source: ConsultantLive - May 9, 2016 Category: Internal Medicine Authors: Mark L. Fuerst Tags: Asthma Source Type: news

An Unusual Cause of Laryngotracheobronchitis
We present a case of pseudomembranous cryptococcal laryngotracheobronchitis in an 80-year-old woman with a history of intractable cough with production of long sputum strings and severe dysphonia. Her main risk factor was considered to be the use of high-dose inhaled fluticasone, given for severe mixed asthma/chronic obstructive pulmonary disease (COPD). This is an unusual presentation of pulmonary cryptococcal disease, which commonly presents as parenchymal disease. We also present a review of the published case reports of endobronchial and laryngeal cryptococcal disease. (Source: Clinical Microbiology Newsletter)
Source: Clinical Microbiology Newsletter - May 5, 2016 Category: Microbiology Authors: Vidthiya Menon, H.E. Jo, P. Corte, A.S. Lee, A.C. Wignall, H.K. Reddel Source Type: news

No Mortality Benefit in COPD With Fluticasone Furoate/Vilanterol No Mortality Benefit in COPD With Fluticasone Furoate/Vilanterol
Patients with COPD and cardiovascular disease risk receiving an inhaled corticosteroid, a long-acting beta agonist, or both showed no difference from placebo in all-cause mortality. Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - May 4, 2016 Category: Allergy & Immunology Tags: Pulmonary Medicine News Source Type: news